DGAP-News

MagForce AG: MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain Cancer

DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG: MagForce AG Announces that Kiel University Hospital
(UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain
Cancer

27.03.2015 / 08:45

---------------------------------------------------------------------

MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated
Commercial NanoTherm(TM) Treatment for Brain Cancer

Berlin, Germany and Nevada, USA, March 27, 2015 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, today announced
that the Department of Neurosurgery at Kiel University Hospital (UKSH),
headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated
NanoTherm(TM) therapy in the commercial setting for the treatment of brain
cancers.

After the start of commercial treatments of brain cancers at the University
Hospital in Munster in February, this marks another milestone for MagForce
with now two world class medical centers offering NanoTherm(TM) therapy
also in the commercial setting.

"Since we announced the first commercial patient in February this year
based on our European approval for the treatment of brain cancer, we have
observed a significantly increased interest of patients, national as well
as international, for the treatment with our innovative NanoTherm(TM)
therapy in Germany. We are especially pleased with the successful
interaction with the key opinion leaders in the medical community.
Preparations for the approval process in the US both for brain cancer and
prostate cancer are well on track, hence, 2015 is set to be a
transformational year for MagForce, marking first commercial revenues and
global expansion," commented Dr. Ben J. Lipps, CEO of MagForce AG and
MagForce USA, Inc.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter